Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion, adding three rare-neurology drugs

Angelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, a U.S. company that develops treatments for rare neurological disorders.

The purchase adds three FDA‑approved medicines to Angelini’s portfolio, including Firdapse for Lambert‑Eaton myasthenic syndrome and Agamree for another rare condition.

The deal broadens Angelini’s neurology franchise and reflects ongoing consolidation in the specialty‑drug market.